Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale

Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophren...

Full description

Saved in:
Bibliographic Details
Published inSchizophrenia research Vol. 274; pp. 337 - 344
Main Authors Ismail, Zahinoor, Meehan, Stine R., Farovik, Anja, Miguelez, Maia, Kapadia, Shivani, Regnier, Stephane Alexandre, Zhang, Zhen, Brown, T. Michelle, Milien, Mirline, McIntyre, Roger S.
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 01.12.2024
Subjects
Online AccessGet full text

Cover

Loading…
Abstract Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia. Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item–total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods. Expert psychiatrists identified 11 relevant items, and patients rated 13 items as “very relevant” to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item–total correlations, 0.35–0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate. A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals.
AbstractList Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia. Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods. Expert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate. A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals.
Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia.BACKGROUNDImproved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research aimed to determine whether certain items from the Positive and Negative Syndrome Scale (PANSS) can assess patient life engagement in schizophrenia.Three approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods.METHODSThree approaches were used to identify PANSS items that reflect patient life engagement: (1) a panel discussion with expert psychiatrists (n = 4); (2) interviews with patients with schizophrenia (n = 20); and (3) a principal component analysis to explore clustering of items (n = 954 from three randomized controlled trials). Internal consistency was assessed by Cronbach's alpha and item-total correlations. A minimal clinically important difference (MCID) was determined by anchor- and distribution-based methods.Expert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate.RESULTSExpert psychiatrists identified 11 relevant items, and patients rated 13 items as "very relevant" to patient life engagement, most of which clustered in the principal component analysis. Considering all results, a composite set of 14 PANSS items that may be relevant to patient life engagement in schizophrenia was devised: P2, N1, N2, N3, N4, N5, N6, N7, G6, G7, G11, G13, G15, G16 (Cronbach's alpha, 0.84; item-total correlations, 0.35-0.56, indicating acceptable correlation with the underlying concept; exception: G6 [depression], 0.19). An MCID of 5 points (small/moderate improvement) or 10 points (large improvement) may be appropriate.A subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals.CONCLUSIONSA subset of 14 PANSS items may be used to reflect patient life engagement in clinical practice/trials in schizophrenia, complementing the results of traditional psychiatric symptom scales with a patient-centered outcome that is relevant to real-world treatment goals.
Author Miguelez, Maia
Meehan, Stine R.
Farovik, Anja
Milien, Mirline
Kapadia, Shivani
McIntyre, Roger S.
Zhang, Zhen
Brown, T. Michelle
Ismail, Zahinoor
Regnier, Stephane Alexandre
Author_xml – sequence: 1
  givenname: Zahinoor
  surname: Ismail
  fullname: Ismail, Zahinoor
  email: ismailz@ucalgary.ca
  organization: Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O'Brien Institute for Public Health, University of Calgary, Calgary, AB, Canada
– sequence: 2
  givenname: Stine R.
  surname: Meehan
  fullname: Meehan, Stine R.
  organization: Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark
– sequence: 3
  givenname: Anja
  surname: Farovik
  fullname: Farovik, Anja
  organization: Global Medical Affairs, H. Lundbeck A/S, Valby, Denmark
– sequence: 4
  givenname: Maia
  surname: Miguelez
  fullname: Miguelez, Maia
  organization: Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA
– sequence: 5
  givenname: Shivani
  surname: Kapadia
  fullname: Kapadia, Shivani
  organization: Global Medical Affairs, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA
– sequence: 6
  givenname: Stephane Alexandre
  surname: Regnier
  fullname: Regnier, Stephane Alexandre
  organization: Value Evidence Analytics and HEOR, H. Lundbeck A/S, Valby, Denmark
– sequence: 7
  givenname: Zhen
  surname: Zhang
  fullname: Zhang, Zhen
  organization: Medical and Real-World Data Analytics, Otsuka Pharmaceutical Development & Commercialization Inc., Princeton, NJ, USA
– sequence: 8
  givenname: T. Michelle
  surname: Brown
  fullname: Brown, T. Michelle
  organization: RTI Health Solutions, Research Triangle Park, NC, USA
– sequence: 9
  givenname: Mirline
  surname: Milien
  fullname: Milien, Mirline
  organization: RTI Health Solutions, Research Triangle Park, NC, USA
– sequence: 10
  givenname: Roger S.
  surname: McIntyre
  fullname: McIntyre, Roger S.
  organization: Mood Disorders Psychopharmacology Unit, University Health Network, University of Toronto, Toronto, ON, Canada
BackLink https://www.ncbi.nlm.nih.gov/pubmed/39461089$$D View this record in MEDLINE/PubMed
BookMark eNp9kE1v1DAQhi1URLeFf4CQj1yy2I4T2xekqiq0UtUi0bvltSdbrxI7eLKVyq_H2y0cOc3XO_NqnjNyknICQj5ytuaM9192a_SPBXAtmJC1tWZMvyEr3qm2ER0zJ2TFjGCNMb08JWeIO8YY75h6R05bI3vOtFmR-QIRECdIC80Dnd0SD-kYB6CQtm4LL6OYaHWLv_NcLVN0dI8xbWlcYEI6lDzR5RHoj4xxiU9AXQr0Drbupfj5nEJV1MS7Ed6Tt4MbET68xnPy8O3q4fK6ub3_fnN5cdv4-o9uTLuRErTWIPuNaqUeVJDc644LP8jO9Ery4FSnXGA6COY6pRxwXQswWrfn5PPx7Fzyrz3gYqeIHsbRJch7tC0XXCglpKpSeZT6khELDHYucXLl2XJmD6jtzh5R2wPqQ7eirmufXh32mwnCv6W_bKvg61EA9c2nCKVeqXA9hFjALzbk-H-HPxxSk_g
Cites_doi 10.1186/s41687-022-00517-z
10.1097/00005053-200010000-00003
10.1177/07067437241233965
10.1016/j.jpsychires.2023.02.008
10.1186/s13075-015-0658-6
10.1186/s41687-021-00380-4
10.1016/j.jpsychires.2023.04.012
10.1017/neu.2020.8
10.1016/j.schres.2010.03.040
10.1001/jama.2015.15818
10.1093/schbul/13.2.261
10.1186/s41687-022-00468-5
10.1017/S0033291723002106
10.1007/s10865-005-9044-1
10.1007/s43441-019-00106-1
10.1186/s13195-018-0381-z
10.5116/ijme.4dfb.8dfd
10.1016/j.schres.2015.01.038
10.1037/a0033813
10.1176/appi.ajp.2015.14101275
10.1017/neu.2016.57
10.1111/j.1369-7625.2011.00704.x
ContentType Journal Article
Copyright 2024 The Authors
Copyright © 2024. Published by Elsevier B.V.
Copyright_xml – notice: 2024 The Authors
– notice: Copyright © 2024. Published by Elsevier B.V.
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
DOI 10.1016/j.schres.2024.10.008
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList PubMed
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
EISSN 1573-2509
EndPage 344
ExternalDocumentID 10_1016_j_schres_2024_10_008
39461089
S0920996424004456
Genre Journal Article
GroupedDBID ---
--K
--M
-~X
.1-
.FO
.GJ
.~1
0R~
123
1B1
1P~
1RT
1~.
1~5
4.4
457
4G.
4H-
53G
5VS
6I.
7-5
71M
8P~
9JM
9JO
AABNK
AACTN
AADFP
AAEDT
AAEDW
AAFTH
AAGJA
AAGUQ
AAIKJ
AAKOC
AALRI
AAOAW
AAQFI
AAQXK
AAWTL
AAXKI
AAXLA
AAXUO
ABBQC
ABCQJ
ABFNM
ABIVO
ABJNI
ABMAC
ABMZM
ABOYX
ABXDB
ACDAQ
ACGFS
ACHQT
ACIUM
ACRLP
ACXNI
ADBBV
ADEZE
ADMUD
AEBSH
AEKER
AENEX
AEVXI
AFCTW
AFJKZ
AFKWA
AFRHN
AFTJW
AFXIZ
AGHFR
AGUBO
AGWIK
AGYEJ
AHHHB
AIEXJ
AIKHN
AITUG
AJOXV
AJRQY
AJUYK
AKRWK
ALMA_UNASSIGNED_HOLDINGS
AMFUW
AMRAJ
ANZVX
ASPBG
AVWKF
AXJTR
AZFZN
BKOJK
BLXMC
BNPGV
CS3
DU5
EBS
EFJIC
EJD
EO8
EO9
EP2
EP3
F5P
FDB
FEDTE
FGOYB
FIRID
FNPLU
FYGXN
G-2
G-Q
GBLVA
HEG
HMK
HMO
HMQ
HMW
HVGLF
HZ~
IHE
J1W
KOM
M29
M2V
M39
M3V
M41
MO0
MOBAO
N9A
O-L
O9-
OAUVE
OH0
OKEIE
OU-
OZT
P-8
P-9
P2P
PC.
Q38
R2-
RIG
ROL
RPZ
SAE
SCC
SDF
SDG
SDP
SEL
SES
SEW
SNS
SPCBC
SPS
SSB
SSH
SSN
SSY
SSZ
T5K
WUQ
Z5R
~G-
NPM
AAYXX
CITATION
7X8
ID FETCH-LOGICAL-c2028-93b44e888e46b7348f7d41c8512cf4596741da757ad08d20a577ae1808de9883
IEDL.DBID AIKHN
ISSN 0920-9964
1573-2509
IngestDate Mon Oct 28 16:45:26 EDT 2024
Wed Nov 06 13:18:10 EST 2024
Sat Nov 02 12:31:40 EDT 2024
Sat Nov 09 15:59:26 EST 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords Schizophrenia
Psychometrics
Life engagement
Patient interview
Minimal clinically important difference
Language English
License This is an open access article under the CC BY license.
Copyright © 2024. Published by Elsevier B.V.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c2028-93b44e888e46b7348f7d41c8512cf4596741da757ad08d20a577ae1808de9883
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
OpenAccessLink https://www.sciencedirect.com/science/article/pii/S0920996424004456
PMID 39461089
PQID 3121277247
PQPubID 23479
PageCount 8
ParticipantIDs proquest_miscellaneous_3121277247
crossref_primary_10_1016_j_schres_2024_10_008
pubmed_primary_39461089
elsevier_sciencedirect_doi_10_1016_j_schres_2024_10_008
PublicationCentury 2000
PublicationDate December 2024
PublicationDateYYYYMMDD 2024-12-01
PublicationDate_xml – month: 12
  year: 2024
  text: December 2024
PublicationDecade 2020
PublicationPlace Netherlands
PublicationPlace_xml – name: Netherlands
PublicationTitle Schizophrenia research
PublicationTitleAlternate Schizophr Res
PublicationYear 2024
Publisher Elsevier B.V
Publisher_xml – name: Elsevier B.V
References McIntyre, Ismail, Watling, Weiss, Meehan, Musingarimi, Thase (bb0095) 2022; 6
Adachi (bb0005) 2016
Correll, Ismail, McIntyre, Rafeyan, Thase (bb0040) 2022; 83
Weldring, Smith (bb0165) 2013; 6
Docherty, Baker, Eudicone, Mathew, Marcus, McQuade, Mankoski (bb0045) 2010; 120
Baran, Docherty (bb0015) 2008
European Medicines Agency (bb0050) 2020
Marder, Eriksson, Zhao, Hobart (bb0090) 2020; 32
Bartrés-Faz, Cattaneo, Solana, Tormos, Pascual-Leone (bb0020) 2018; 10
Therrien, Ward, Chokka, Habert, Ismail, McIntyre, MacKenzie (bb0145) 2024; 69
Scheier, Wrosch, Baum, Cohen, Martire, Matthews, Schulz, Zdaniuk (bb0125) 2006; 29
Vita, Barlati, Deste, Nibbio, Penn, Pinkham, McIntyre, Harvey (bb0155) 2023; 53
Guy (bb0055) 1976
R Core Team (bb0115) 2022
Kieffer, Miller, Chacko, Robertson (bb0080) 2020; 54
Therrien, Meehan, Weiss, Dine, Brown, MacKenzie (bb0140) 2022; 6
Thase, Ismail, Meehan, Weiss, Regnier, Larsen, McIntyre (bb0135) 2023; 161
Correll, Ismail, McIntyre, Rafeyan, Thase (bb0035) 2022; 83
Purnine, Carey, Maisto, Carey (bb0110) 2000; 188
Kane, Skuban, Ouyang, Hobart, Pfister, McQuade, Nyilas, Carson, Sanchez, Eriksson (bb0070) 2015; 164
Kay, Fiszbein, Opler (bb0075) 1987; 13
Tavakol, Dennick (bb0130) 2011; 2
Opler, Yavorsky, Daniel (bb0105) 2017; 14
Jolliffe (bb0065) 2002
Rai, Yazdany, Fortin, Aviña-Zubieta (bb0120) 2015; 17
Correll, Skuban, Ouyang, Hobart, Pfister, McQuade, Nyilas, Carson, Sanchez, Eriksson (bb0030) 2015; 172
Weiss, Meehan, Brown, Gupta, Mørup, Thase, McIntyre, Ismail (bb0160) 2021; 5
Hunter, O’Callaghan, Califf (bb0060) 2015; 314
Marder, Hakala, Josiassen, Zhang, Ouyang, Weiller, Weiss, Hobart (bb0085) 2017; 29
Bridges, Slawik, Schmeding, Reimer, Naber, Kuhnigk (bb0025) 2013; 16
McIntyre, Therrien, Ismail, Meehan, Miguelez, Larsen, Chen, MacKenzie, Thase (bb0100) 2023; 162
Trompetter, Ten Klooster, Schreurs, Fledderus, Westerhof, Bohlmeijer (bb0150) 2013; 25
American Psychiatric Association (bb0010) 2000
Tavakol (10.1016/j.schres.2024.10.008_bb0130) 2011; 2
Weldring (10.1016/j.schres.2024.10.008_bb0165) 2013; 6
European Medicines Agency (10.1016/j.schres.2024.10.008_bb0050) 2020
R Core Team (10.1016/j.schres.2024.10.008_bb0115)
Kay (10.1016/j.schres.2024.10.008_bb0075) 1987; 13
Scheier (10.1016/j.schres.2024.10.008_bb0125) 2006; 29
Correll (10.1016/j.schres.2024.10.008_bb0030) 2015; 172
McIntyre (10.1016/j.schres.2024.10.008_bb0100) 2023; 162
Therrien (10.1016/j.schres.2024.10.008_bb0145) 2024; 69
Bartrés-Faz (10.1016/j.schres.2024.10.008_bb0020) 2018; 10
Correll (10.1016/j.schres.2024.10.008_bb0040) 2022; 83
Jolliffe (10.1016/j.schres.2024.10.008_bb0065) 2002
Vita (10.1016/j.schres.2024.10.008_bb0155) 2023; 53
Correll (10.1016/j.schres.2024.10.008_bb0035) 2022; 83
Marder (10.1016/j.schres.2024.10.008_bb0085) 2017; 29
Kane (10.1016/j.schres.2024.10.008_bb0070) 2015; 164
Rai (10.1016/j.schres.2024.10.008_bb0120) 2015; 17
American Psychiatric Association (10.1016/j.schres.2024.10.008_bb0010) 2000
Thase (10.1016/j.schres.2024.10.008_bb0135) 2023; 161
Docherty (10.1016/j.schres.2024.10.008_bb0045) 2010; 120
McIntyre (10.1016/j.schres.2024.10.008_bb0095) 2022; 6
Opler (10.1016/j.schres.2024.10.008_bb0105) 2017; 14
Baran (10.1016/j.schres.2024.10.008_bb0015)
Bridges (10.1016/j.schres.2024.10.008_bb0025) 2013; 16
Kieffer (10.1016/j.schres.2024.10.008_bb0080) 2020; 54
Trompetter (10.1016/j.schres.2024.10.008_bb0150) 2013; 25
Purnine (10.1016/j.schres.2024.10.008_bb0110) 2000; 188
Adachi (10.1016/j.schres.2024.10.008_bb0005) 2016
Marder (10.1016/j.schres.2024.10.008_bb0090) 2020; 32
Hunter (10.1016/j.schres.2024.10.008_bb0060) 2015; 314
Guy (10.1016/j.schres.2024.10.008_bb0055) 1976
Therrien (10.1016/j.schres.2024.10.008_bb0140) 2022; 6
Weiss (10.1016/j.schres.2024.10.008_bb0160) 2021; 5
References_xml – volume: 25
  start-page: 1235
  year: 2013
  end-page: 1246
  ident: bb0150
  article-title: Measuring values and committed action with the Engaged Living Scale (ELS): psychometric evaluation in a nonclinical sample and a chronic pain sample
  publication-title: Psychol. Assess.
  contributor:
    fullname: Bohlmeijer
– volume: 29
  start-page: 278
  year: 2017
  end-page: 290
  ident: bb0085
  article-title: Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
  publication-title: Acta Neuropsychiatr.
  contributor:
    fullname: Hobart
– volume: 54
  start-page: 709
  year: 2020
  end-page: 716
  ident: bb0080
  article-title: FDA reported use of patient experience data in 2018 drug approvals
  publication-title: Ther. Innov. Regul. Sci.
  contributor:
    fullname: Robertson
– volume: 53
  start-page: 7943
  year: 2023
  end-page: 7952
  ident: bb0155
  article-title: Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community
  publication-title: Psychol. Med.
  contributor:
    fullname: Harvey
– volume: 188
  start-page: 653
  year: 2000
  end-page: 661
  ident: bb0110
  article-title: Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders
  publication-title: J. Nerv. Ment. Dis.
  contributor:
    fullname: Carey
– volume: 29
  start-page: 291
  year: 2006
  end-page: 298
  ident: bb0125
  article-title: The Life Engagement Test: assessing purpose in life
  publication-title: J. Behav. Med.
  contributor:
    fullname: Zdaniuk
– volume: 13
  start-page: 261
  year: 1987
  end-page: 276
  ident: bb0075
  article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
  publication-title: Schizophr. Bull.
  contributor:
    fullname: Opler
– year: 2008
  ident: bb0015
  article-title: The “A” effect of aripiprazole. Presented at the American Psychiatric Association meeting. Washington, DC, May 3–8 2008
  contributor:
    fullname: Docherty
– volume: 10
  start-page: 47
  year: 2018
  ident: bb0020
  article-title: Meaning in life: resilience beyond reserve
  publication-title: Alzheimers Res. Ther.
  contributor:
    fullname: Pascual-Leone
– volume: 2
  start-page: 53
  year: 2011
  end-page: 55
  ident: bb0130
  article-title: Making sense of Cronbach’s alpha
  publication-title: Int. J. Med. Educ.
  contributor:
    fullname: Dennick
– year: 1976
  ident: bb0055
  article-title: ECDEU Assessment Manual for Psychopharmacology, Revised
  contributor:
    fullname: Guy
– volume: 6
  start-page: 62
  year: 2022
  ident: bb0095
  article-title: Patient-reported outcome measures for life engagement in mental health: a systematic review
  publication-title: J. Patient Rep. Outcomes
  contributor:
    fullname: Thase
– volume: 164
  start-page: 127
  year: 2015
  end-page: 135
  ident: bb0070
  article-title: A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
  publication-title: Schizophr. Res.
  contributor:
    fullname: Eriksson
– volume: 17
  start-page: 143
  year: 2015
  ident: bb0120
  article-title: Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
  publication-title: Arthritis Res. Ther.
  contributor:
    fullname: Aviña-Zubieta
– volume: 5
  start-page: 128
  year: 2021
  ident: bb0160
  article-title: Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder:
  publication-title: J. Patient Rep. Outcomes
  contributor:
    fullname: Ismail
– volume: 162
  start-page: 71
  year: 2023
  end-page: 78
  ident: bb0100
  article-title: Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder:
  publication-title: J. Psychiatr. Res.
  contributor:
    fullname: Thase
– volume: 83
  year: 2022
  ident: bb0040
  article-title: Patient functioning, life engagement, and treatment goals in schizophrenia
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Thase
– year: 2022
  ident: bb0115
  article-title: R: a language and environment for statistical computing
  contributor:
    fullname: R Core Team
– volume: 161
  start-page: 132
  year: 2023
  end-page: 139
  ident: bb0135
  article-title: Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR)
  publication-title: J. Psychiatr. Res.
  contributor:
    fullname: McIntyre
– volume: 83
  year: 2022
  ident: bb0035
  article-title: Patient functioning and life engagement: unmet needs in major depressive disorder and schizophrenia
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Thase
– start-page: 145
  year: 2016
  end-page: 160
  ident: bb0005
  article-title: Confirmatory factor analysis
  publication-title: Matrix-Based Introduction to Multivariate Data Analysis
  contributor:
    fullname: Adachi
– year: 2002
  ident: bb0065
  article-title: Principal Component Analysis
  contributor:
    fullname: Jolliffe
– volume: 6
  start-page: 61
  year: 2013
  end-page: 68
  ident: bb0165
  article-title: Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)
  publication-title: Health. Serv. Insights
  contributor:
    fullname: Smith
– volume: 14
  start-page: 77
  year: 2017
  end-page: 81
  ident: bb0105
  article-title: Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions
  publication-title: Innov. Clin. Neurosci.
  contributor:
    fullname: Daniel
– volume: 314
  start-page: 2499
  year: 2015
  end-page: 2500
  ident: bb0060
  article-title: Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration
  publication-title: JAMA
  contributor:
    fullname: Califf
– year: 2020
  ident: bb0050
  article-title: ICH Reflection Paper on Proposed ICH Guideline Work to Advance Patient Focused Drug Development
  contributor:
    fullname: European Medicines Agency
– volume: 6
  start-page: 111
  year: 2022
  ident: bb0140
  article-title: Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews
  publication-title: J. Patient Rep. Outcomes
  contributor:
    fullname: MacKenzie
– volume: 69
  start-page: 513
  year: 2024
  end-page: 523
  ident: bb0145
  article-title: Adjunctive brexpiprazole for patient life engagement in major depressive disorder: a Canadian, phase 4, open-label, interventional study
  publication-title: Can. J. Psychiatry
  contributor:
    fullname: MacKenzie
– volume: 16
  start-page: 164
  year: 2013
  end-page: 176
  ident: bb0025
  article-title: A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia
  publication-title: Health Expect.
  contributor:
    fullname: Kuhnigk
– volume: 172
  start-page: 870
  year: 2015
  end-page: 880
  ident: bb0030
  article-title: Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial
  publication-title: Am. J. Psychiatry
  contributor:
    fullname: Eriksson
– volume: 120
  start-page: 199
  year: 2010
  end-page: 203
  ident: bb0045
  article-title: Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia
  publication-title: Schizophr. Res.
  contributor:
    fullname: Mankoski
– volume: 32
  start-page: 153
  year: 2020
  end-page: 158
  ident: bb0090
  article-title: analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia
  publication-title: Acta Neuropsychiatr.
  contributor:
    fullname: Hobart
– year: 2000
  ident: bb0010
  article-title: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision
  contributor:
    fullname: American Psychiatric Association
– volume: 6
  start-page: 111
  year: 2022
  ident: 10.1016/j.schres.2024.10.008_bb0140
  article-title: Exploring life engagement from the perspective of patients with major depressive disorder: a study using patient interviews
  publication-title: J. Patient Rep. Outcomes
  doi: 10.1186/s41687-022-00517-z
  contributor:
    fullname: Therrien
– volume: 188
  start-page: 653
  year: 2000
  ident: 10.1016/j.schres.2024.10.008_bb0110
  article-title: Assessing positive and negative symptoms in outpatients with schizophrenia and mood disorders
  publication-title: J. Nerv. Ment. Dis.
  doi: 10.1097/00005053-200010000-00003
  contributor:
    fullname: Purnine
– volume: 69
  start-page: 513
  year: 2024
  ident: 10.1016/j.schres.2024.10.008_bb0145
  article-title: Adjunctive brexpiprazole for patient life engagement in major depressive disorder: a Canadian, phase 4, open-label, interventional study
  publication-title: Can. J. Psychiatry
  doi: 10.1177/07067437241233965
  contributor:
    fullname: Therrien
– volume: 161
  start-page: 132
  year: 2023
  ident: 10.1016/j.schres.2024.10.008_bb0135
  article-title: Assessment of patient life engagement in major depressive disorder using items from the Inventory of Depressive Symptomatology Self-Report (IDS-SR)
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/j.jpsychires.2023.02.008
  contributor:
    fullname: Thase
– volume: 17
  start-page: 143
  year: 2015
  ident: 10.1016/j.schres.2024.10.008_bb0120
  article-title: Approaches for estimating minimal clinically important differences in systemic lupus erythematosus
  publication-title: Arthritis Res. Ther.
  doi: 10.1186/s13075-015-0658-6
  contributor:
    fullname: Rai
– volume: 5
  start-page: 128
  year: 2021
  ident: 10.1016/j.schres.2024.10.008_bb0160
  article-title: Effects of adjunctive brexpiprazole on calmness and life engagement in major depressive disorder: post hoc analysis of patient-reported outcomes from clinical trial exit interviews
  publication-title: J. Patient Rep. Outcomes
  doi: 10.1186/s41687-021-00380-4
  contributor:
    fullname: Weiss
– volume: 162
  start-page: 71
  year: 2023
  ident: 10.1016/j.schres.2024.10.008_bb0100
  article-title: Effects of adjunctive brexpiprazole on patient life engagement in major depressive disorder: post hoc analysis of Inventory of Depressive Symptomatology Self-Report data
  publication-title: J. Psychiatr. Res.
  doi: 10.1016/j.jpsychires.2023.04.012
  contributor:
    fullname: McIntyre
– volume: 83
  year: 2022
  ident: 10.1016/j.schres.2024.10.008_bb0035
  article-title: Patient functioning and life engagement: unmet needs in major depressive disorder and schizophrenia
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Correll
– volume: 32
  start-page: 153
  year: 2020
  ident: 10.1016/j.schres.2024.10.008_bb0090
  article-title: Post hoc analysis of a randomised, placebo-controlled, active-reference 6-week study of brexpiprazole in acute schizophrenia
  publication-title: Acta Neuropsychiatr.
  doi: 10.1017/neu.2020.8
  contributor:
    fullname: Marder
– year: 2002
  ident: 10.1016/j.schres.2024.10.008_bb0065
  contributor:
    fullname: Jolliffe
– volume: 120
  start-page: 199
  year: 2010
  ident: 10.1016/j.schres.2024.10.008_bb0045
  article-title: Effect of aripiprazole versus haloperidol on PANSS Prosocial items in early-episode patients with schizophrenia
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2010.03.040
  contributor:
    fullname: Docherty
– volume: 314
  start-page: 2499
  year: 2015
  ident: 10.1016/j.schres.2024.10.008_bb0060
  article-title: Engaging patients across the spectrum of medical product development: view from the US Food and Drug Administration
  publication-title: JAMA
  doi: 10.1001/jama.2015.15818
  contributor:
    fullname: Hunter
– start-page: 145
  year: 2016
  ident: 10.1016/j.schres.2024.10.008_bb0005
  article-title: Confirmatory factor analysis
  contributor:
    fullname: Adachi
– volume: 13
  start-page: 261
  year: 1987
  ident: 10.1016/j.schres.2024.10.008_bb0075
  article-title: The Positive and Negative Syndrome Scale (PANSS) for schizophrenia
  publication-title: Schizophr. Bull.
  doi: 10.1093/schbul/13.2.261
  contributor:
    fullname: Kay
– ident: 10.1016/j.schres.2024.10.008_bb0015
  contributor:
    fullname: Baran
– volume: 6
  start-page: 62
  year: 2022
  ident: 10.1016/j.schres.2024.10.008_bb0095
  article-title: Patient-reported outcome measures for life engagement in mental health: a systematic review
  publication-title: J. Patient Rep. Outcomes
  doi: 10.1186/s41687-022-00468-5
  contributor:
    fullname: McIntyre
– volume: 53
  start-page: 7943
  year: 2023
  ident: 10.1016/j.schres.2024.10.008_bb0155
  article-title: Life engagement in people living with schizophrenia: predictors and correlates of patient life engagement in a large sample of people living in the community
  publication-title: Psychol. Med.
  doi: 10.1017/S0033291723002106
  contributor:
    fullname: Vita
– volume: 83
  year: 2022
  ident: 10.1016/j.schres.2024.10.008_bb0040
  article-title: Patient functioning, life engagement, and treatment goals in schizophrenia
  publication-title: J. Clin. Psychiatry
  contributor:
    fullname: Correll
– volume: 6
  start-page: 61
  year: 2013
  ident: 10.1016/j.schres.2024.10.008_bb0165
  article-title: Patient-reported outcomes (PROs) and patient-reported outcome measures (PROMs)
  publication-title: Health. Serv. Insights
  contributor:
    fullname: Weldring
– volume: 14
  start-page: 77
  year: 2017
  ident: 10.1016/j.schres.2024.10.008_bb0105
  article-title: Positive and Negative Syndrome Scale (PANSS) training: challenges, solutions, and future directions
  publication-title: Innov. Clin. Neurosci.
  contributor:
    fullname: Opler
– volume: 29
  start-page: 291
  year: 2006
  ident: 10.1016/j.schres.2024.10.008_bb0125
  article-title: The Life Engagement Test: assessing purpose in life
  publication-title: J. Behav. Med.
  doi: 10.1007/s10865-005-9044-1
  contributor:
    fullname: Scheier
– volume: 54
  start-page: 709
  year: 2020
  ident: 10.1016/j.schres.2024.10.008_bb0080
  article-title: FDA reported use of patient experience data in 2018 drug approvals
  publication-title: Ther. Innov. Regul. Sci.
  doi: 10.1007/s43441-019-00106-1
  contributor:
    fullname: Kieffer
– year: 2000
  ident: 10.1016/j.schres.2024.10.008_bb0010
  contributor:
    fullname: American Psychiatric Association
– volume: 10
  start-page: 47
  year: 2018
  ident: 10.1016/j.schres.2024.10.008_bb0020
  article-title: Meaning in life: resilience beyond reserve
  publication-title: Alzheimers Res. Ther.
  doi: 10.1186/s13195-018-0381-z
  contributor:
    fullname: Bartrés-Faz
– volume: 2
  start-page: 53
  year: 2011
  ident: 10.1016/j.schres.2024.10.008_bb0130
  article-title: Making sense of Cronbach’s alpha
  publication-title: Int. J. Med. Educ.
  doi: 10.5116/ijme.4dfb.8dfd
  contributor:
    fullname: Tavakol
– year: 2020
  ident: 10.1016/j.schres.2024.10.008_bb0050
  contributor:
    fullname: European Medicines Agency
– ident: 10.1016/j.schres.2024.10.008_bb0115
  contributor:
    fullname: R Core Team
– volume: 164
  start-page: 127
  year: 2015
  ident: 10.1016/j.schres.2024.10.008_bb0070
  article-title: A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia
  publication-title: Schizophr. Res.
  doi: 10.1016/j.schres.2015.01.038
  contributor:
    fullname: Kane
– volume: 25
  start-page: 1235
  year: 2013
  ident: 10.1016/j.schres.2024.10.008_bb0150
  article-title: Measuring values and committed action with the Engaged Living Scale (ELS): psychometric evaluation in a nonclinical sample and a chronic pain sample
  publication-title: Psychol. Assess.
  doi: 10.1037/a0033813
  contributor:
    fullname: Trompetter
– volume: 172
  start-page: 870
  year: 2015
  ident: 10.1016/j.schres.2024.10.008_bb0030
  article-title: Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial
  publication-title: Am. J. Psychiatry
  doi: 10.1176/appi.ajp.2015.14101275
  contributor:
    fullname: Correll
– year: 1976
  ident: 10.1016/j.schres.2024.10.008_bb0055
  contributor:
    fullname: Guy
– volume: 29
  start-page: 278
  year: 2017
  ident: 10.1016/j.schres.2024.10.008_bb0085
  article-title: Brexpiprazole in patients with schizophrenia: overview of short- and long-term phase 3 controlled studies
  publication-title: Acta Neuropsychiatr.
  doi: 10.1017/neu.2016.57
  contributor:
    fullname: Marder
– volume: 16
  start-page: 164
  year: 2013
  ident: 10.1016/j.schres.2024.10.008_bb0025
  article-title: A test of concordance between patient and psychiatrist valuations of multiple treatment goals for schizophrenia
  publication-title: Health Expect.
  doi: 10.1111/j.1369-7625.2011.00704.x
  contributor:
    fullname: Bridges
SSID ssj0001507
Score 2.4965265
Snippet Improved patient life engagement is a meaningful treatment goal in schizophrenia that cannot be satisfactorily measured using existing tools. This research...
SourceID proquest
crossref
pubmed
elsevier
SourceType Aggregation Database
Index Database
Publisher
StartPage 337
SubjectTerms Life engagement
Minimal clinically important difference
Patient interview
Psychometrics
Schizophrenia
Title Assessment of patient life engagement in schizophrenia using items from the Positive and Negative Syndrome Scale
URI https://dx.doi.org/10.1016/j.schres.2024.10.008
https://www.ncbi.nlm.nih.gov/pubmed/39461089
https://www.proquest.com/docview/3121277247
Volume 274
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Na-MwEB2a9LKXpWW7u9l-MAu9prFl2ZKPoTSkWxoW0kJuRrbkkGVxwvbj2N_eGVkO7SEU9miBsJiRZ97Ib54AzqneUhXlEYp-ouajGzXMLXdymcgIEddW-1tLbmfZ9F7-WqSLPbjsemGYVhlifxvTfbQOI6NgzdFmtRrNo5zbPgk_8zYkHNCDfUpHQvdhf3x9M51tAzJjHi-5R5UST-g66DzNi2pIqmupUBTywtO89K4MtQuB-kw0OYDPAULiuF3lIey55gtsxluJTVzXGORS8e-qduiaZaC44KrBh7c0O2Te-xL9fWzIrSZIgBB_eybXs0PTWJy5pRcHx3kQN8A5-dUdwd3k6u5yOgy3KQwrwUdoeVJK6ajgdTIrWdOmVlbGFSEuUdUyzTPCFtaoVBkbaSsikyplXKzpweVaJ1-h36wb9x3QCqXKpEpdlGhpE1kqnZbSVCorqd7K5ACGnQGLTauZUXRksj9Fa_CCDc6jZPABqM7KxTvfFxTWP5j5s3NKQZ8F_-swjVs_PRRJzNL1Skg1gG-tt7ZrSXIWmdf5j_9-7zF84qeW1nIC_cd_T-6UwMljeQa9i5f4LGzBV53g4q8
link.rule.ids 315,783,787,4509,24128,27936,27937,45597,45691
linkProvider Elsevier
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LS8QwEA4-DnoRxdf6HMHrut00bdLjIsr6WoRdwVtIm3RZke7iqr_fmTRd9CCCl0JTQstMMvkm_eYLY-eYb8kC1xGMfrykrRvZzixVcpnIcN4trfKnljwM0v6TuH1OnpfYZVMLQ7TKEPvrmO6jdWjpBGt2ZpNJZxhlVPaJ-JmGIeKAZbaK1wxn52rv5q4_WARkwjxecg8zJerQVNB5mhfmkJjXYqLIxYWneanfVqjfEKhfia432UaAkNCrv3KLLblqm816C4lNmJYQ5FLhdVI6cNU4UFxgUsH8O80OiPc-Bn8eG1CpCSAghEfP5Pp0YCoLAzf24uAwDOIGMES_uh02ur4aXfbb4TSFdsFpCy2LcyEcJrxOpDlp2pTSim6BiIsXpUiyFLGFNTKRxkbK8sgkUhrXVXjjMqXiXbZSTSu3z8ByKfO4SFwUK2FjkUuV5MIUMs0x30pFi7UbA-pZrZmhGzLZi64Nrsng1IoGbzHZWFn_8L3GsP5Hz7PGKRqnBf3rMJWbfsx13CXpesmFbLG92luLb4kzEplX2cG_33vK1vqjh3t9fzO4O2Tr9KSmuByxlfe3D3eMQOU9PwkD8QscA-Sj
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Assessment+of+patient+life+engagement+in+schizophrenia+using+items+from+the+Positive+and+Negative+Syndrome+Scale&rft.jtitle=Schizophrenia+research&rft.au=Ismail%2C+Zahinoor&rft.au=Meehan%2C+Stine+R&rft.au=Farovik%2C+Anja&rft.au=Miguelez%2C+Maia&rft.date=2024-12-01&rft.eissn=1573-2509&rft.volume=274&rft.spage=337&rft_id=info:doi/10.1016%2Fj.schres.2024.10.008&rft_id=info%3Apmid%2F39461089&rft.externalDocID=39461089
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0920-9964&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0920-9964&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0920-9964&client=summon